Patent intelligence · AU
AU 2011260615
Oral dosage forms of bendamustine
Oral dosage forms of bendamustine
Patent details — AU 2011260615
- Jurisdiction
- AU
- Status
- granted
- Grant date
- Jan 10, 2013
- Expiration
- Jan 5, 2033
- Applicant
- ASTELLAS DEUTSCHLAND GMBH [CH]
- CPC classes
- A61K 9/ 14 A I, A61K 9/ 48 A I, A61K 31/ 4184 A I, A61K 47/ 10 A I
Quick answer
AU 2011260615 (Oral dosage forms of bendamustine) is held by ASTELLAS DEUTSCHLAND GMBH [CH]. Status: granted. Granted Jan 10, 2013. Expires Jan 5, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ASTELLAS DEUTSCHLAND GMBH [CH]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 14 A I, A61K 9/ 48 A I, A61K 31/ 4184 A I, A61K 47/ 10 A I, A61K/314184, A61K/4506
More from ASTELLAS DEUTSCHLAND GMBH [CH]
Related pharmaceutical patents in our USPTO index.
-
AU 2022206771
Drug conjugates comprising antibodies against Claudin 18.2
granted -
EP 3791896
KOMBINATIONSTHERAPIE MIT ANTIKÖRPERN GEGEN CLAUDIN 18.2 ZUR BEHANDLUNG VON KREBS
granted -
LT 3254695
COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
granted -
EP 3708579
CLAUDIN-6-SPEZIFISCHE IMMUNREZPTOREN UND T-ZELL-EPITOPE
granted -
HR P20200591
ANTIBODIES SPECIFIC FOR CLAUDIN 6 (CLDN6)
granted -
US 2020199221
ANTIBODIES USEFUL IN CANCER DIAGNOSIS
granted -
WO 2020095183
COMBINAISON POUR LE TRAITEMENT DU CANCER
granted -
US 2019076525
THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
granted
Frequently asked questions
What is US patent 2011260615?
AU 2011260615 (Oral dosage forms of bendamustine) is held by ASTELLAS DEUTSCHLAND GMBH [CH]. Status: granted. Granted Jan 10, 2013. Expires Jan 5, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns AU 2011260615?
ASTELLAS DEUTSCHLAND GMBH [CH] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does AU 2011260615 expire?
Our index shows an expiration date of Jan 5, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.